RNTX

Rein Therapeutics, Inc. (RNTX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases. The company's lead product candidate, LTI-03, is in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis (IPF). The company paused development of its second candidate, LTI-01, indefinitely in late 2025 to prioritize LTI-03. As of the filing date, the company had 85,539,032 shares of common stock outstanding.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no revenue and has never generated an operating profit.

Material Changes vs. Prior Period

• Financing Activity: In Q1 2026, the company issued unsecured promissory notes with an aggregate principal of approximately $5.38 million, receiving net proceeds of $4.30 million. This contrasts with Q1 2025, which had no debt issuance.
• Operating Expenses: Total operating expenses decreased by $0.38 million to $5.23 million. This was driven by a $0.40 million decrease in General and Administrative (G&A) expenses (primarily lower legal fees), partially offset by a slight increase in Research and Development (R&D) expenses.
• Cash Flow: Net cash used in operating activities improved significantly to $3.42 million in Q1 2026 compared to $6.18 million in Q1 2025, largely due to a $2.29 million increase in accounts payable.
• Other Income/Expense: The company reported a net expense of $0.61 million in Q1 2026 compared to income of $0.11 million in Q1 2025, primarily due to the amortization of the discount on the new notes payable.

Guidance, Outlook, and Risks

• Clinical Progress: The company dosed its first patient in the Phase 2 RENEW trial for LTI-03 in March 2026. Interim topline data is anticipated in the fourth quarter of 2026.
• Liquidity and Capital Resources: As of March 31, 2026, the company held $4.45 million in cash. Management believes this, combined with proceeds from a subsequent May 2026 public offering (see below), will fund operations into the first quarter of 2028.
• Subsequent Event (May 2026 Offering): Following the quarter end, the company completed an underwritten public offering of 57.5 million shares at $1.00 per share, raising approximately $53.1 million in net proceeds. These funds were used to repay the Q1 2026 promissory notes in full.
• Internal Controls: The company identified material weaknesses in its internal control over financial reporting, citing a lack of sufficient accounting personnel and inadequate procedures for timely financial statement preparation. Remediation efforts are ongoing.
• Risks: The company faces significant risks related to its ability to raise additional capital, the success of the LTI-03 clinical trial, and the indefinite pause of the LTI-01 program.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $53.1 million raised in May 2026 to fund the Phase 2 RENEW trial and operations through Q1 2028 as projected by management.
• Debt Repayment: Confirm the full repayment of the $5.38 million principal notes issued in Q1 2026 using the proceeds from the May 2026 offering.
• Internal Control Remediation: Monitor the progress of remediation plans for the identified material weaknesses in financial reporting controls.
• Clinical Milestones: Track patient enrollment rates and the timeline for the anticipated Q4 2026 interim data release for LTI-03.
• Share Dilution: Note the significant increase in outstanding shares (from ~28 million at quarter-end to ~85.5 million post-offering) and the impact on future earnings per share.